ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented At ASCO

June 3, 2009

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced the presentation of encouraging trastuzumab-DM1 (T-DM1) clinical data at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Orlando, Florida.

T-DM1, an antibody-drug conjugate, consists of ImmunoGen’s DM1 cancer-cell killing agent linked to the HER2-targeted antibody, trastuzumab, developed by Genentech, Inc. (a wholly-owned member of the Roche Group). Genentech (US) and Roche (ex-US) are conducting a broad clinical program with T-DM1 in HER2-positive breast cancer.
Read the rest of this entry »

Advertisements

Gene Network Sciences Announces Broad Cancer Collaboration With UCSF And Initial Results

June 1, 2009

Gene Network Sciences, Inc. (GNS) announced that it has entered into a research collaboration with the University of California San Francisco Cancer Center (UCSF) aimed at accelerating cancer research and drug development across several therapeutic areas. This collaboration will combine the clinical and research oncology expertise of UCSF with the computational expertise and supercomputer-driven REFS(TM) platform of GNS. Financial terms of the agreement were not disclosed.
Read the rest of this entry »


Catalyst Pharmaceutical Partners Announces Top-Line Results Of CPP-109 Phase II Trial For Cocaine Addiction

June 1, 2009

Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced top-line results from its U.S. Phase II clinical trial to treat cocaine addiction. The data from the trial showed that CPP-109 did not demonstrate statistical significance in the primary endpoint — that a significantly larger proportion of CPP-109-treated subjects than placebo-treated subjects were cocaine-free during the last two weeks of the treatment period (Weeks 11 and 12). The clinical trial did not reveal any unexpected “serious” adverse events.
Read the rest of this entry »


Gene Network Sciences Announces Broad Cancer Collaboration With UCSF And Initial Results

June 1, 2009

Gene Network Sciences, Inc. (GNS) announced that it has entered into a research collaboration with the University of California San Francisco Cancer Center (UCSF) aimed at accelerating cancer research and drug development across several therapeutic areas. This collaboration will combine the clinical and research oncology expertise of UCSF with the computational expertise and supercomputer-driven REFS(TM) platform of GNS. Financial terms of the agreement were not disclosed.
Read the rest of this entry »


The Gout & Uric Acid Education Society (GUAES) Announces New Survey Results Highlighting Major Gaps In Public Awareness Of Gout

May 25, 2009

The Gout & Uric Acid Education Society announced that new survey results reveal alarming gaps in the public’s awareness of gout, a painful and potentially debilitating form of arthritis that affects three to five million Americans. In a survey of more than 2,000 Americans, 65% of adults admitted to being “not at all knowledgeable” about gout and just over 70% did not know that gout is a form of arthritis. In fact, gout is the most common form of inflammatory arthritis among adults.
Read the rest of this entry »


Bovie Medical Corporation Announces FDA Submission Of Laparoscopic Device For Solid Organ Resection

May 23, 2009

Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, announced a 510K submission to the FDA seeking pre-market clearance for a laparoscopic SEER device for solid organ resection. The laparoscopic SEER is a line extension of the Saline Enhance Electrosurgical Resection (SEER) device that Bovie launched earlier this year and will address the growing market of minimally invasive liver resection.
Read the rest of this entry »


SANE Australia Announces Book Of The Year Award

May 16, 2009

SANE Australia is pleased to announce the 2009 SANE Book of the Year is Back From The Brink Too: Supporting Your Loved One In Overcoming Depression by Graeme Cowan.

The SANE Book of the Year Award recognises outstanding Australian non-fiction titles which promote understanding of mental illness and its effect in the community. Previous winners include Anne Deveson AO for Tell Me I’m Here and Craig Hamilton for Broken Open. Read the rest of this entry »